Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and high risk to recurrence and metastasis. After the appearance of anti-HER2 targeted drugs, the prognosis and survival of these patients were greatly improved. In addition to trastuzumab and pertuzumab, the use of tyrosine kinase inhibitor (TKI) can further improve the survival. The evidence of previous adjuvant TKI anti-HER2 therapy was mainly from ExteNET study. However, due to the limitations of the times, ExteNET research is based on the background of only trastuzumab targeted therapy. Nowadays, there is no evidence that trastuzumab combined patuzumab,use of T-DM1, followed by sequential neratinib can still obtain absolute benefits. Therefore, there is no standard for the use of neratinib in current clinical practice. Investigators want to explore, in the real world, the efficacy and safety of sequential use of naratinib in adjuvant therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Diagnoza raka piersi HER2-dodatniego potwierdzona biopsją lub operacją w szpitalu
- •Pacjent był leczony w naszym szpitalu i przeszedł całkowite usunięcie guza
- •Otrzymał standardowe leczenie przeciw HER2 (trastuzumab, trastuzumab z pertuzumabem lub T-DM1)
- •Podpisał zgodę na udział w badaniu kohorty chorób piersi
✗ Disqualifies
- •Brak pełnych danych klinicznych i wyników badań (zdjęcia, wyniki patologii)
- •Rak piersi z przerzutami do innych organów lub rak obustronny
- •Pacjent nie przeszedł całkowitej operacji chirurgicznej
Simplified criteria — AI translation
Trial details
- Last updated (source)
- November 20, 2024
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Peking University People's Hospital
Beijing, China
Trial contact
yuan peng, doctor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.